Immune dysregulation as a driver of idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) affects hundreds of thousands of people worldwide, reducing their quality of life and leading to death from respiratory failure within years of diagnosis. Treatment options remain limited, with only two FDA-approved drugs available in the United States, neither of...

Full description

Saved in:
Bibliographic Details
Published in:J Clin Invest
Main Authors: Shenderov, Kevin, Collins, Samuel L., Powell, Jonathan D., Horton, Maureen R.
Format: Artigo
Language:Inglês
Published: American Society for Clinical Investigation 2021
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7810481/
https://ncbi.nlm.nih.gov/pubmed/33463535
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI143226
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items